{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:13:14Z","timestamp":1772853194220,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40615-025-02350-8","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:55:27Z","timestamp":1741254927000},"page":"1503-1512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization and Cancer Control Outcomes of Active Surveillance Amongst Black and White Men with Intermediate Risk Prostate Cancer in a Population-Based Analysis"],"prefix":"10.1007","volume":"13","author":[{"given":"Shane A.","family":"Tinsley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chase","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keinnan","family":"Hares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lutchka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Abdollah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"1","key":"2350_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. \u201cCancer statistics, 2023,\u201d (in eng). CA Cancer J Clin. J 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2350_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5534\/wjmh.210070","volume":"40","author":"N Hinata","year":"2022","unstructured":"Hinata N, Fujisawa M. \u201cRacial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview,\u201d (in eng). World J Mens Health. A 2022;40(2):217\u201327. https:\/\/doi.org\/10.5534\/wjmh.210070.","journal-title":"World J Mens Health"},{"issue":"5","key":"2350_CR3","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.juro.2010.01.015","volume":"183","author":"IJ Powell","year":"2010","unstructured":"Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. \u201cEvidence supports a faster growth rate and\/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity,\u201d (in eng). J Urol. M 2010;183(5):1792\u20136. https:\/\/doi.org\/10.1016\/j.juro.2010.01.015.","journal-title":"J Urol"},{"issue":"2","key":"2350_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.6004\/jnccn.2010.0010","volume":"8","author":"JL Mohler","year":"2010","unstructured":"Mohler JL. \u201cThe 2010 NCCN clinical practice guidelines in oncology on prostate cancer,\u201d (in eng). J Natl Compr Canc Netw. F 2010;8(2):145. https:\/\/doi.org\/10.6004\/jnccn.2010.0010.","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"2350_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, et al. \u201c10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer,\u201d (in eng). N Engl J Med. 2016;375(15):1415\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1606220.","journal-title":"N Engl J Med"},{"issue":"17","key":"2350_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, et al. \u201cFifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer,\u201d (in eng). N Engl J Med. 2023;388(17):1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"key":"2350_CR7","doi-asserted-by":"publisher","unstructured":"L. F. Newcomb et al., \"Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer,\" (in eng), JAMA, May 30 2024, https:\/\/doi.org\/10.1001\/jama.2024.6695.","DOI":"10.1001\/jama.2024.6695"},{"issue":"17","key":"2350_CR8","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jama.2020.17020","volume":"324","author":"R Deka","year":"2020","unstructured":"Deka R, et al. \u201cAssociation Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance,\u201d (in eng). JAMA. 2020;324(17):1747\u201354. https:\/\/doi.org\/10.1001\/jama.2020.17020.","journal-title":"JAMA"},{"issue":"1","key":"2350_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJMc2306135","volume":"389","author":"MJ Davis","year":"2023","unstructured":"Davis MJ, Stephens A, Abdollah F. \u201cFifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer,\u201d (in eng). N Engl J Med. 2023;389(1):90\u20132. https:\/\/doi.org\/10.1056\/NEJMc2306135.","journal-title":"N Engl J Med"},{"issue":"9","key":"2350_CR10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamainternmed.2015.2835","volume":"175","author":"MJ Maurice","year":"2015","unstructured":"Maurice MJ, Abouassaly R, Kim SP, Zhu H. \u201cContemporary Nationwide Patterns of Active Surveillance Use for Prostate Cancer,\u201d (in eng). JAMA Intern Med. S 2015;175(9):1569\u201371. https:\/\/doi.org\/10.1001\/jamainternmed.2015.2835.","journal-title":"JAMA Intern Med"},{"key":"2350_CR11","doi-asserted-by":"publisher","unstructured":"M. R. Cooperberg, W. Meeks, R. Fang, F. D. Gaylis, W. J. Catalona, and D. V. Makarov, \"Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US,\" (in eng), JAMA Netw Open, vol. 6, no. 3, p. e231439, Mar 01 2023, https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.1439.","DOI":"10.1001\/jamanetworkopen.2023.1439"},{"key":"2350_CR12","doi-asserted-by":"publisher","unstructured":"B. Al Hussein Al Awamlh et al., \"Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018,\" (in eng), JAMA Intern Med, vol. 183, no. 6, pp. 608\u2013611, Jun 01 2023, https:\/\/doi.org\/10.1001\/jamainternmed.2022.7100.","DOI":"10.1001\/jamainternmed.2022.7100"},{"issue":"6","key":"2350_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","volume":"5","author":"M Baboudjian","year":"2022","unstructured":"Baboudjian M, et al. \u201cActive Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression,\u201d (in eng). Eur Urol Oncol. D 2022;5(6):617\u201327. https:\/\/doi.org\/10.1016\/j.euo.2022.07.004.","journal-title":"Eur Urol Oncol"},{"key":"2350_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.urology.2021.05.068","volume":"155","author":"T Chandrasekar","year":"2021","unstructured":"Chandrasekar T, et al. \u201cOutcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis,\u201d (in eng). Urology. S 2021;155:101\u20139. https:\/\/doi.org\/10.1016\/j.urology.2021.05.068.","journal-title":"Urology"},{"issue":"18","key":"2350_CR15","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1002\/cncr.32202","volume":"125","author":"SS Butler","year":"2019","unstructured":"Butler SS, et al. \u201cUse and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer,\u201d (in eng). Cancer. 2019;125(18):3164\u201371. https:\/\/doi.org\/10.1002\/cncr.32202.","journal-title":"Cancer"},{"issue":"3","key":"2350_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2014.284","volume":"1","author":"AC Raldow","year":"2015","unstructured":"Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D\u2019Amico AV. \u201cRisk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer,\u201d (in eng). JAMA Oncol. J 2015;1(3):334\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2014.284.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2350_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00345-022-04228-4","volume":"41","author":"RK Sayyid","year":"2023","unstructured":"Sayyid RK, et al. \u201cProstate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis,\u201d (in eng). World J Urol. J 2023;41(1):93\u20139. https:\/\/doi.org\/10.1007\/s00345-022-04228-4.","journal-title":"World J Urol"},{"issue":"3","key":"2350_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/UPJ.0000000000000529","volume":"11","author":"SP Basourakos","year":"2024","unstructured":"Basourakos SP, et al. \u201cRacial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer,\u201d (in eng). Urol Pract. M 2024;11(3):538\u201346. https:\/\/doi.org\/10.1097\/UPJ.0000000000000529.","journal-title":"Urol Pract"},{"key":"2350_CR19","unstructured":"\"Surveillance, Epidemiology, and End Results Program.\" Surveillance, Epidemiology, and End Results Program (cancer.gov) (accessed December 19, 2023)."},{"key":"2350_CR20","unstructured":"\"Prostate cancer with additional treatment and risk stratification fields database.\" Surveillance, Epidemiology, and End Results. https:\/\/seer.cancer.gov\/data\/specialized\/available-databases\/prostate-request\/ (accessed May 20, 2024)."},{"key":"2350_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","volume":"2","author":"DB Rubin","year":"2001","unstructured":"Rubin DB. Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation. Health Serv Outcomes Res Method. 2001;2:169\u201388. https:\/\/doi.org\/10.1023\/A:1020363010465.","journal-title":"Health Serv Outcomes Res Method"},{"key":"2350_CR22","doi-asserted-by":"publisher","unstructured":"E. M. Schaeffer et al., \"NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 1.2023,\" (in eng), J Natl Compr Canc Netw, vol. 20, no. 12, pp. 1288\u20131298, Dec 2022, https:\/\/doi.org\/10.6004\/jnccn.2022.0063.","DOI":"10.6004\/jnccn.2022.0063"},{"issue":"1","key":"2350_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, et al. \u201cClinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up,\u201d (in eng). J Urol. J 2022;208(1):19\u201325. https:\/\/doi.org\/10.1097\/JU.0000000000002758.","journal-title":"J Urol"},{"issue":"1","key":"2350_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/JU.0000000000001241","volume":"205","author":"V Agrawal","year":"2021","unstructured":"Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H. \u201cActive Surveillance for Men with Intermediate Risk Prostate Cancer,\u201d (in eng). J Urol. J 2021;205(1):115\u201321. https:\/\/doi.org\/10.1097\/JU.0000000000001241.","journal-title":"J Urol"},{"issue":"10","key":"2350_CR25","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/cam4.1132","volume":"6","author":"RR Parikh","year":"2017","unstructured":"Parikh RR, Kim S, Stein MN, Haffty BG, Kim IY, Goyal S. \u201cTrends in active surveillance for very low-risk prostate cancer: do guidelines influence modern practice?,\u201d (in eng). Cancer Med. O 2017;6(10):2410\u20138. https:\/\/doi.org\/10.1002\/cam4.1132.","journal-title":"Cancer Med"},{"issue":"21","key":"2350_CR26","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1056\/NEJMc1900333","volume":"380","author":"S Butler","year":"2019","unstructured":"Butler S, et al. \u201cActive Surveillance for Low-Risk Prostate Cancer in Black Patients,\u201d (in eng). N Engl J Med. 2019;380(21):2070\u20132. https:\/\/doi.org\/10.1056\/NEJMc1900333.","journal-title":"N Engl J Med"},{"issue":"23","key":"2350_CR27","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1002\/cncr.33824","volume":"127","author":"PT Courtney","year":"2021","unstructured":"Courtney PT, et al. \u201cActive surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men,\u201d (in eng). Cancer. 2021;127(23):4403\u201312. https:\/\/doi.org\/10.1002\/cncr.33824.","journal-title":"Cancer"},{"key":"2350_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.euros.2023.02.002","volume":"50","author":"MV Sherer","year":"2023","unstructured":"Sherer MV, et al. \u201cPrognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance,\u201d (in eng). Eur Urol Open Sci. A 2023;50:61\u20137. https:\/\/doi.org\/10.1016\/j.euros.2023.02.002.","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"2350_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.euo.2021.07.006","volume":"5","author":"BA Mahal","year":"2022","unstructured":"Mahal BA, et al. \u201cProstate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel,\u201d (in eng). Eur Urol Oncol. F 2022;5(1):18\u201329. https:\/\/doi.org\/10.1016\/j.euo.2021.07.006.","journal-title":"Eur Urol Oncol"}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-025-02350-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-025-02350-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-025-02350-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:09:29Z","timestamp":1772809769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-025-02350-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2350"],"URL":"https:\/\/doi.org\/10.1007\/s40615-025-02350-8","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempt from Internal Board Review approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"None applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors approve of this manuscript for submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"None of the authors have any relevant disclosures, and none of the authors have any financial or non-financial interests that may be relevant to the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}